martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 30, 2026

Stocks to watch next week: Alphabet, Amazon, Palantir, Novo Nordisk and Shell

View original at uk.finance.yahoo.com
Stocks to watch next week: Alphabet, Amazon, Palantir, Novo Nordisk and Shell Two more "Magnificent 7" companies are set to report in the week ahead, along other key players in tech, in another jam-packed week of earnings…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Amazon expects net sales in Q4 to be between $206bn and $213bn, representing 10% to 13% growth on the same period a year earlier

    80% confidence
  • Alphabet expected capex to be in the range of $91bn to $93bn for the year, as stated in Q3 results

    80% confidence
  • Amazon expects Q4 operating income to be between $21bn and $26bn, compared to $21.2bn for Q4 2024

    80% confidence
  • Shell is now undergoing more conservative capital expenditure, underpinning shareholder returns, and its diversity of operations allows one area of strength to counter another of weakness

    80% confidence
  • There could be some upside to consensus forecasts of a small fall in 2026 Novo Nordisk sales

    80% confidence
  • Google Cloud is facing stiff competition in the AI arms race against other dominant AI infrastructure platforms like Microsoft's Azure

    80% confidence
  • Shell's 5% gain over the past year rates as outperformance given that it was achieved despite the fall in oil price, boosted by a 3.9% dividend yield and $3.5bn per quarter buyback programme

    80% confidence
  • Shell's chemicals and products division trading results are expected to be significantly lower than Q3

    80% confidence
  • Last time around, AWS demand was still running ahead of available capacity as new infrastructure struggled to keep up

    80% confidence
  • Palantir expects to report adjusted operating income of $695m to $699m for Q4

    80% confidence
  • It's been a promising start to 2026, with take-up of Wegovy pill helping to claw back some US market share from arch-rival Eli Lilly

    80% confidence
  • Markets are pencilling in AWS growth of around 21% for Q4, which would mark a third consecutive quarter of acceleration

    80% confidence
  • Palantir expects Q4 revenue to be between $1.327bn and $1.331bn

    80% confidence
  • Investor sentiment towards Novo Nordisk bottomed out following another downgrade to revenue and profit guidance at its Q3 update in November

    80% confidence
  • Focus in Alphabet's earnings will be on capital expenditure, cloud numbers, and any guidance around AI investment and demand

    80% confidence
  • Novo's full-year revenue is now expected to have risen 8% to 11%, ignoring exchange rate moves, while operating profit growth is expected at 4% to 7%

    80% confidence
  • Shell's dividend could be sustained even with the oil price as low as $40 per barrel

    80% confidence
  • Shell remains the preferred play in the energy sector over BP

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
Stocks to watch next week: Alphabet, Amazon, Palantir, Novo Nordisk and Shell — Source | Via News | es.VIA.NEWS